6th Neurological Disorders Summit (NDS-2021) was held virtually from June 21-23, 2021, organized by United Scientific Group, a nonprofit organization. This three-day conference had gathered 115 participants from 25 countries; had 30 oral presentations and 35 poster presentations and more than 50 delegates on a wide variety of topics on Neurological Disorders and the related fields. Here are the highlights of some topics in the Summit.
The keynote session on Day 1 started with the talk of Dr. Zang-Hee Cho (Seoul National University, South Korea) who developed world’s first circular ring PET, presented on “Ultra-High Field PET-MRI Imaging for Neurological Disorders– from Parkinson’s to Alzheimer’s”. Jin Jun Luo (Temple University, PA, USA) given keynote talked on “Homocysteine and Dementia in Parkinson disease”, suggesting Parkinson’s and dementia are neurodegenerative disorders that are frequently seen in the elderly. Homocysteine (Hcy) is an intermediary metabolite from methylation, which is highly relevant to body physiologic activities including DNA metabolism. Yury Chernoff (Georgia Institute of Technology, Georgia, USA) elaborated “Yeast Models for Studying Aggregation of Proteins, Involved in Alzheimer’s disease” suggested Cross-β fibrous aggregates (amyloids) is implicated in a variety of human diseases. Some amyloids possess transmissible (prion) properties. Amyloid formation by Aβ and tau proteins has been linked to Alzheimer’s disease. Perrier Veronique (University of Montpellier, France) talked on “Fungicide Residues Exacerbate β-amyloid Aggregates and Vascular Amyloid Antipathy in a Mouse Model of Alzheimer’s disease” and told how pesticide residues have contaminated our environment and nutrition over the last century and suggested that the presence of these residues can long term effect on human health is of concern. Dr. Veronique told link between pesticide residues and Alzheimer’s disease is not clear but it is the future research of interest. Kathrine Black (Biocrates Life Sciences AG, Austria) one of our sponsor talked on “argeted Metabolomics - Understanding the Role of the Microbiome in Neurological Diseases” establish connection between gut microbial dysbiosis and pathophysiologies governing neurodegeneration in several CNS disorders. His organisation Biocrates Life Sciences work on the targeted metabolomics technology to enabled meaningful advances in the study of Alzheimer’s and Parkinson’s diseases. The first day of the meeting continued with sessions on "Dementia, Parkinson’s, Mild Cognitive Impairment, Neurological and Neurodegenerative Diseases", and “Parkinson’s, Alzheimer’s and Neurological Disorders" with 20 speakers and poster presenters presenting their recent research work. In the session of Dementia, Parkinson’s, Mild Cognitive Impairment, Neurological and Neurodegenerative Diseases, studies and reviews were presented including Andres Ricaurte-Fajardo (Pontifical Xaverian University/Hospital Universitario Fundación Santa Fe de Bogota, Colombia) on “Reversible Cerebral Vasoconstriction Syndrome Associated with Anastrozole: An Unusual Cause of High Impact”; Florence Roussel (Nationwide Children’s Hospital, OH, USA) on “Mitochondrial and Metabolic Activity Analyses Across Several Neurological and Neurodegenerative Disorders Identify Common Therapeutic Targets”; Shrestha Sinha Ray (Nationwide Children’s Hospital, OH, USA) on “Identification of a Novel Disease Mechanism and a Potential Treatment for Newly Discovered Neurodevelopmental Disease “NEDAMSS”; Cassandra Dennys-Rivers (Nationwide Children’s Hospital, OH, USA) on a debatable topic “ALS Patient Skin Derived iAstroctytes Predicts CuATSM Responsiveness Neurodegenerative Diseases”; Maya Koronyo-Hamaoui (Cedars-Sinai Medical Center, LA, USA) on “Retinal Amyloid Imaging in a Cohort of Patients with Mild Cognitive Impairment and Alzheimer’s disease”; Betty M. Tyler (Johns Hopkins University, USA) on “ Drug Delivery and Repurposing for Brain Tumor Therapy”; Cassandra Terry (London Metropolitan University, London) on “Recent Advances in Understanding Mammalian Prion Structure” and Jason DeBoard (Wilkes University, PA, USA) presented a poster with his team on “Characterization and Correlation of Neurodegeneration and Biological Markers of Model Mice with Traumatic Brain Injury and Alzheimer’s Disease”. The session of “Parkinson’s, Alzheimer’s and Neurological Disorders” had interesting presentations from Han Yang (Beijing Sports University, China) on “Effects of Health Qigong on Shoulder and Hip Joint Range of Motion, Daily Activities and Motor Function in Patients with Parkinson’s Disease”; Yury Chernoff (Georgia Institute of Technology, Georgia) on “Yeast Models for Studying Aggregation of Proteins, Involved in Alzheimer’s disease”; Perrier Véronique (University of Montpellier, France) on “Fungicide Residues Exacerbate β-amyloid Aggregates and Vascular Amyloid Angiopathy in a Mouse Model of Alzheimer’s disease”; Kathrine Black (Biocrates Life Sciences AG, Austria) on “Targeted Metabolomics - Understanding the Role of the Microbiome in Neurological Diseases”; and some posters presented by Mireia Cara Esteban (University of Valencia, Spain) on “Morphological Analysis of New Cytopathological Hallmarks in Dopaminergic Enteric Neurons of Parkinson’s disease”; Vikash Jaiswal (Larkin Health System, FL, USA) on “WHO Grade III Anaplastic Astrocytoma In A 72 Years Old Male-A Case Report”; Ranga Krishna (TotalNeuroCare, NY, USA) on “ The Melting Pot of Moyamoya Disease: Lessons from a Challenging Case”; Tania C Ghazarian (Western University of Health Sciences College of Osteopathic Medicine of the Pacific, CA, USA) on “Perseveration and Anterograde Amnesia: The Broken Record Phenomenon“;. The Day 2 was highlighted with the series of interesting talk in different sessions on “Alzheimer’s, Disease and Neurodegenerative Diseases", "Parkinson’s Disease and Other Movement Disorders", "Neurological Disorders: Prevention, Treatments and Rehabilitation" and "Stroke, Aging, Autism and Neurodevelopemental Disorders" kept the audience engaged with discussions. Some of the notable presentations of the day 2 session were from Shui Yin Lo (Quantum Health Research Institute, CA, USA) on “Inflammation of Organs in Autistic Children”; Rajendra Badgaiyan (South Texas Veteran Health Care System, Audie L. Murphy Memorial VA Hospital, San Antonio, TX, USA) on “A Novel Method for Identification of Dysregulated Neurotransmission in Dementia”; Jun Li (University of Texas Health Science Center Houston, TX, USA) on “Stroke-induced Respiratory Dysfunction and Cognitive Decline: Influence of Sex and Age “ and Kenneth Blum (Western University College of Medicine, CA, USA) on “Reward Deficiency Syndrome (RDS) A Cytoarchival Octopus of All Addictive Behaviors”. In the session related to Alzheimer’s, Parkinson’s and Neurodegenerative Diseases has started presentations from Rui Yang (Beijing Sports University, China) on “Effects of Health Qigong Exercise on Motor Function in Patients with Parkinson’s Disease”; Felix-Martin Werner (Euro Akademy Pobneck, Germany) on “Updated Neural Networks in Generalized Epilepsy and Novel Antiepileptic Drugs”; Siyaram Pandey (University of Windsor, Canada) on “Activation of Autophagy, Inhibition of Inflammation and Amelioration of Behavioural Deficit by Ubisol-Q10 in AD Fibroblasts and Tg(APPswe,PSEN1dE9) Mice”; Caleb Vegh, (University of Windsor, Canada) on “Targeting Multiple Biochemical Mechanisms with a Novel Nutraceutical Combinatorial Therapy to Halt Neurodegeneration in Parkinson’s Disease” and end with some innovative poster presentations from Guofu Wang ( Zhejiang Hospital, China) on “Application of Artificial Intelligence in the Prevention, Diagnosis and Treatment of Alzheimer’s disease: New Hope for Dealing with Ageing in China”; Chenhaoyi Xu (Tongji University, China) on “METTL3 Facilitates Arc Expression via YTHDF1-mediated m6A Modification”; Vikash Jaiswal (Larkin Health System, FL) on “Influence of Novel Coronavirus Disease (COVID-19) on Parkinson’s Disease: A systematic Review”. In the session of Stroke, Aging, Autism and Neurodevelopemental Disorders: Darcy Wear (University of Windsor, Canada) presented on “Ubisol-Q10 Induced Autophagy Resumption Ameliorates AD Pathologies in Presenilin-1 Mutated Fibroblasts and Transgenic AD Mice”; Jun Li (University of Texas Health Science Center Houston, TX) on “Stroke-induced Respiratory Dysfunction and Cognitive Decline: Influence of Sex and Age” and Shin Murakami (Touro University California, CA, USA) presented on “The Genes linking Dementia and Age-related Comorbidity”. Poster presentations from Christina Shincovich (George Washington University School of Medicine and Health Sciences, WA, USA) on “Assessing Ketorolac Analgesic Effect in Postoperative Pectus Excavatum and Pectus Carinatum Patients: An Observational Study”; Salvador-Prince Lucie (University of Montpellier, INM, France) on “Prenatal Exposure to Low Doses of Fungicides Corrupts Neurogenesis in Neonates” and Jonathan Quinonez (Larkin Community Hospital, FL, USA) on “Von Recklinghausen Disease – Seizures and Gliomas – A Case Report” were among the notable poster presentations in the session of Stroke, Aging, Autism and Neurodevelopemental Disorders. Last day of the summit was mainly focused on "Parkinson’s, Autism, Dementia and Multiple Sclerosis" with 5 notable speakers and 8 poster presenters. The session of Parkinson’s, Autism, Dementia and Multiple Sclerosis had presentations started from speakers Fang Li (Chinese Traditional Regimen Exercise Intervention Research Center, China) on “Study on the Improvement of Health Qigong on Nocturnal Sleep Disorder of Parkinson’s disease Patients”; Xiaolei Liu (Beijing Sport University, China) on “The Intervention Study of Health Qigong Exercise on Depression and Anxiety of Parkinson’s Disease Patients”; Urszula Wojda (Nencki Institute of Experimental Biology of Polish Academy of Sciences, Poland) on “Alzheimer’s Disease Candidate Biomarkers miR-483-5p and miR-200a-3p Control Tau Phosphorylation and Amyloidogenesis”; Jose Alonso Aguilar-Valera (Kazan Federal University, Russian Federation) on “Neuropsychological Assessment, Diagnosis and Clinical Intervention of Autistic Spectrum Disorder (ASD)” and Shun Yao (Harvard Medical School) on “Hormone Levels are Associated with Altered Brain Structure and Functional Connectivity in Prolactinomas”; and end with some poster presentations: Haoyue Deng (Army Medical University, China) on “Resveratrol Alleviates Aβ25–35 Caused Neurotoxicity via Autophagy Induction”; Natalia Cherevko (Siberian State Medical University, Russia) on “Features of Cytokine Changes and Food Reactions in Children with Autism”; Amr M. El (Alexandria University, Egypt) on “The Added Value of Delayed T1 Post Contrast Sequence in Diagnosis of Multiple Sclerosis”; Syra Mehdi (Alzheimer’s Disease Center, MA) on “Chromosomal Sex Differences in Tau Levels in Patients Attending a Memory Clinic”; Fang He (Texas A&M University, Kingsville, TX) on “The Modulation of Expanded GGCCTG Repeats Toxicity by Surrounding Sequences in Fly Models of SCA36”; Marta Andres-Mach (Institute of Rural Health, Poland) on “C11, A Novel 2-(2,5-dioxopyrrolidin-1-yl) propanamide Derivative as A Candidate for a Broad-spectrum Antiepileptic Drug: Its Impact on Neurogenesis, Neurodegeneration and Cognitive Functions in Mice”; Dina Ayman ElZohiry (University of New Haven, CT) on “Evaluating the Link between Alzheimer Associated-APOE Variants and Lyme Disease”; Kimberly Rosenthal (University of Central Florida College of Medicine, FL) on “Concussion Severity in Pediatric mTBI from Organized vs Non-organized Sports as Measured by Serum GFAP and UCH-L1”. NDS-2021 served an excellent platform for researchers, scientist, learners and trainees, and industrials to exchange information of their research advances, build networking, display the modern technologies, new products in the field of Neurological Disorders, and the service of the industry to the worldwide audience. The 7th Neurological Disorders Summit will be held on July 18-20, 2022 in San Francisco, California, USA. We look forward to having your active contribution and seeing you at the NDS-2022. We are glad to announce the 7th Neurological Disorders Summit (NDS-2022) which will be scheduled for July 18-20, 2022 in San Francisco, CA.
We look forward to having your active contribution and support for the success of NDS-2022.